Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc. has successfully raised approximately $750,000 through a non-brokered private placement of over 4 million units at $0.18 each, with each unit comprising a common share and a purchase warrant. The funds are earmarked for their Phase II clinical study on non-muscle invasive bladder cancer, preclinical research on Rutherrin®, and for general corporate purposes. The securities issued will be subjected to a four-month holding period, with final acceptance from the TSX Venture Exchange pending.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
